The API intermediate market is projected to grow strongly, reaching $220.78 billion by 2030 at a 7.4% CAGR, driven by CDMO partnerships, reshoring, and pharma R&D expansion.
Read MoreThe acquired autoimmune hemolytic anemia market is set for strong growth, reaching $3.01 billion by 2030 at a 7.1% CAGR, driven by biologics and advanced diagnostics.
Read MoreThe acne drugs market is set for steady growth, reaching $7.71 billion by 2030 at a 4.2% CAGR, driven by novel formulations, OTC expansion, and personalized dermatology.
Read MoreThe acetaminophen-opioid combination market is expected to reach $4.06 billion by 2030 at a 4.9% CAGR, shaped by opioid regulations, stewardship programs, and acute pain management needs.
Read MoreThe ACE inhibitors market is set for strong growth, reaching $10.11 billion by 2030 at a 6.5% CAGR, driven by personalized care, generics, and digital health adoption.
Read MoreThe abortion drugs market is poised for rapid growth, reaching $54.85 billion by 2030 at an 11.2% CAGR, driven by telehealth expansion and rising demand for medical abortion.
Read MoreAbemaciclib market to reach $2.84 billion by 2030 at 12.1% CAGR, driven by increasing incidence of breast cancer and treatment demand.
Read MoreThe 3D bioprinted human tissue market is set for rapid growth, reaching $3.59 billion by 2030 at a 13.2% CAGR, driven by regenerative medicine and advanced drug testing.
Read More2D cell culture market to reach $8.44 billion by 2030 at 9.7% CAGR, driven by growing need for high-throughput screening.
Read MoreThe Cancer Supportive Care Drugs market size is expected to reach $25.93 billion in 2030 at a CAGR of 3.7%, driven by improved cancer survival rates.
Read More